CMS wants to narrow Medicare drug plan options
Executive Summary
CMS is looking at ways to further "focus the number" of Medicare Part D drug plans to "really meaningful differences with respect to benefit plans and formularies," Tracey McCutcheon, deputy director of the agency's Medicare Drug Benefit Group, said at a Nov. 5 Alliance for Health Reform event. She said later that CMS is collecting data to "find a basis for cutting down on so many options," though it is struggling "to find a policy reason to negotiate away bids." For 2007 and 2008, CMS asked sponsors to limit bids to two plans unless a third plan offered a meaningful difference, such as gap coverage...
You may also be interested in...
Part D Challenges Described By CMS Official Reflect A Mature Program
The main challenges facing Medicare Part D are those of a mature program as it enters its fifth year of providing prescription drug benefits
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.